FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385693606> ?p ?o ?g. }

• W4385693606 endingPage "1815" @default.
• W4385693606 startingPage "1807" @default.
• W4385693606 abstract "OBJECTIVE To develop a risk assessment tool to identify patients with type 2 diabetes (T2D) at higher risk for kidney disease progression and who might benefit more from sodium–glucose cotransporter 2 (SGLT2) inhibition. RESEARCH DESIGN AND METHODS A total of 41,204 patients with T2D from four Thrombolysis In Myocardial Infarction (TIMI) clinical trials were divided into derivation (70%) and validation cohorts (30%). Candidate predictors of kidney disease progression (composite of sustained ≥40% decline in estimated glomerular filtration rate [eGFR], end-stage kidney disease, or kidney death) were selected with multivariable Cox regression. Efficacy of dapagliflozin was assessed by risk categories (low: &lt;0.5%; intermediate: 0.5 to &lt;2%; high: ≥2%) in Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58. RESULTS There were 695 events over a median follow-up of 2.4 years. The final model comprised eight independent predictors of kidney disease progression: atherosclerotic cardiovascular disease, heart failure, systolic blood pressure, T2D duration, glycated hemoglobin, eGFR, urine albumin-to-creatinine ratio, and hemoglobin. The c-indices were 0.798 (95% CI, 0.774–0.821) and 0.798 (95% CI, 0.765–0.831) in the derivation and validation cohort, respectively. The calibration plot slope (deciles of predicted vs. observed risk) was 0.98 (95% CI, 0.93–1.04) in the validation cohort. Whereas relative risk reductions with dapagliflozin did not differ across risk categories, there was greater absolute risk reduction in patients with higher baseline risk, with a 3.5% absolute risk reduction in kidney disease progression at 4 years in the highest risk group (≥1%/year). Results were similar with the 2022 Chronic Kidney Disease Prognosis Consortium risk prediction model. CONCLUSIONS Risk models for kidney disease progression can be applied in patients with T2D to stratify risk and identify those who experience a greater magnitude of benefit from SGLT2 inhibition." @default.
• W4385693606 created "2023-08-10" @default.
• W4385693606 creator A5020677154 @default.
• W4385693606 creator A5022267024 @default.
• W4385693606 creator A5026004870 @default.
• W4385693606 creator A5030057930 @default.
• W4385693606 creator A5045238618 @default.
• W4385693606 creator A5045516967 @default.
• W4385693606 creator A5048789881 @default.
• W4385693606 creator A5058503662 @default.
• W4385693606 creator A5067426250 @default.
• W4385693606 creator A5069050485 @default.
• W4385693606 creator A5069388270 @default.
• W4385693606 creator A5073517018 @default.
• W4385693606 creator A5080475619 @default.
• W4385693606 date "2023-08-09" @default.
• W4385693606 modified "2023-09-26" @default.
• W4385693606 title "Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes" @default.
• W4385693606 cites W2044773944 @default.
• W4385693606 cites W2056976690 @default.
• W4385693606 cites W2064130493 @default.
• W4385693606 cites W2086570276 @default.
• W4385693606 cites W2092433795 @default.
• W4385693606 cites W2118561903 @default.
• W4385693606 cites W2123893097 @default.
• W4385693606 cites W2136840691 @default.
• W4385693606 cites W2155965977 @default.
• W4385693606 cites W2165817472 @default.
• W4385693606 cites W2234357320 @default.
• W4385693606 cites W2339565048 @default.
• W4385693606 cites W2424539745 @default.
• W4385693606 cites W2475261460 @default.
• W4385693606 cites W2596179513 @default.
• W4385693606 cites W2607031541 @default.
• W4385693606 cites W2626446274 @default.
• W4385693606 cites W2888628330 @default.
• W4385693606 cites W2900413769 @default.
• W4385693606 cites W2939222610 @default.
• W4385693606 cites W2951812067 @default.
• W4385693606 cites W2968073288 @default.
• W4385693606 cites W2986999055 @default.
• W4385693606 cites W3088173406 @default.
• W4385693606 cites W3094429645 @default.
• W4385693606 cites W3096486083 @default.
• W4385693606 cites W3129954143 @default.
• W4385693606 cites W3142577573 @default.
• W4385693606 cites W3185976379 @default.
• W4385693606 cites W4281634119 @default.
• W4385693606 cites W4286001091 @default.
• W4385693606 cites W4292731103 @default.
• W4385693606 cites W4308183941 @default.
• W4385693606 cites W4308291843 @default.
• W4385693606 doi "https://doi.org/10.2337/dc23-0492" @default.
• W4385693606 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37556796" @default.
• W4385693606 hasPublicationYear "2023" @default.
• W4385693606 type Work @default.
• W4385693606 citedByCount "0" @default.
• W4385693606 crossrefType "journal-article" @default.
• W4385693606 hasAuthorship W4385693606A5020677154 @default.
• W4385693606 hasAuthorship W4385693606A5022267024 @default.
• W4385693606 hasAuthorship W4385693606A5026004870 @default.
• W4385693606 hasAuthorship W4385693606A5030057930 @default.
• W4385693606 hasAuthorship W4385693606A5045238618 @default.
• W4385693606 hasAuthorship W4385693606A5045516967 @default.
• W4385693606 hasAuthorship W4385693606A5048789881 @default.
• W4385693606 hasAuthorship W4385693606A5058503662 @default.
• W4385693606 hasAuthorship W4385693606A5067426250 @default.
• W4385693606 hasAuthorship W4385693606A5069050485 @default.
• W4385693606 hasAuthorship W4385693606A5069388270 @default.
• W4385693606 hasAuthorship W4385693606A5073517018 @default.
• W4385693606 hasAuthorship W4385693606A5080475619 @default.
• W4385693606 hasBestOaLocation W43856936061 @default.
• W4385693606 hasConcept C11783203 @default.
• W4385693606 hasConcept C126322002 @default.
• W4385693606 hasConcept C134018914 @default.
• W4385693606 hasConcept C159641895 @default.
• W4385693606 hasConcept C207103383 @default.
• W4385693606 hasConcept C2777180221 @default.
• W4385693606 hasConcept C2777422806 @default.
• W4385693606 hasConcept C2777538456 @default.
• W4385693606 hasConcept C2777995511 @default.
• W4385693606 hasConcept C2778653478 @default.
• W4385693606 hasConcept C2779134260 @default.
• W4385693606 hasConcept C2780306776 @default.
• W4385693606 hasConcept C2780400711 @default.
• W4385693606 hasConcept C44249647 @default.
• W4385693606 hasConcept C500558357 @default.
• W4385693606 hasConcept C555293320 @default.
• W4385693606 hasConcept C71924100 @default.
• W4385693606 hasConceptScore W4385693606C11783203 @default.
• W4385693606 hasConceptScore W4385693606C126322002 @default.
• W4385693606 hasConceptScore W4385693606C134018914 @default.
• W4385693606 hasConceptScore W4385693606C159641895 @default.
• W4385693606 hasConceptScore W4385693606C207103383 @default.
• W4385693606 hasConceptScore W4385693606C2777180221 @default.
• W4385693606 hasConceptScore W4385693606C2777422806 @default.
• W4385693606 hasConceptScore W4385693606C2777538456 @default.
• W4385693606 hasConceptScore W4385693606C2777995511 @default.

• next